Laura Q.M. Chow
Seattle Cancer Care Alliance
2 papers in the Anchorcite directory, published between 2012 and 2015, cited 17,527 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 2 papers
- Lung Cancer Diagnosis and Treatment · 1 paper
- Lung Cancer Treatments and Mutations · 1 paper
- T-cell and B-cell Immunology · 1 paper
- Immunotherapy and Immune Responses · 1 paper
Frequent co-authors
- Julie Renee Brahmer · 2 papers
- Hossein Borghaei · 1 paper
- Luis G Paz-Ares · 1 paper
- Leora Horn · 1 paper
- David Robert Spigel · 1 paper
- Martin B. Steins · 1 paper
- Neal Ready · 1 paper
- Everett E. Vokes · 1 paper
Papers
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 9,473 citations
BACKGROUND: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had…
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine · 2012 · 8,054 citations
BACKGROUND: Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune system. Blockade of interactions between PD-1 and PD-L1 enhances…
Metadata from OpenAlex (CC0).